As I expected, FDA clearance for InVivage now is (hopefully) a 2025 approval. With all the other things going on with OIL as detailed in this presentation, very exciting, but from my, admittedly cheap seats, view, it is a slow 2024 coming from a revenue perspective. However, happy they have survived through tough times and continually doing amazing things on the tech side of things.
I am concerned on the push on the US office/sales team with the oral device so far in the future. But there is so much going on with the company now, I assume management have a way to keep costs managed well enough with sales with other tech.
How do others see this presentation?
Ann: OIL Managing Director's Presentation & Chair's Address, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.015(7.50%) |
Mkt cap ! $179.5M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 22.0¢ | 20.0¢ | $67.20K | 322.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 45149 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 26834 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| OIL (ASX) Chart |